Santen Pharmaceutical Co., Ltd.
SNPHF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $467,400 | $68,737,000 | $77,231,000 | $76,369,000 |
| % Growth | -99.3% | -11% | 1.1% | – |
| Cost of Goods Sold | $211,791 | $31,619,000 | $31,135,000 | $34,135,000 |
| Gross Profit | $255,609 | $37,118,000 | $46,096,000 | $42,234,000 |
| % Margin | 54.7% | 54% | 59.7% | 55.3% |
| R&D Expenses | $41,669 | $6,207,000 | $7,330,000 | $5,829,000 |
| G&A Expenses | $0 | $0 | $1,399,000 | $0 |
| SG&A Expenses | $144,069 | $21,204,000 | $22,565,000 | $22,488,000 |
| Sales & Mktg Exp. | $0 | $0 | $17,410,000 | $0 |
| Other Operating Expenses | $0 | $2,134,000 | $6,338,000 | $2,134,000 |
| Operating Expenses | $185,738 | $29,545,000 | $36,233,000 | $30,451,000 |
| Operating Income | $69,871 | $7,573,000 | $9,863,000 | $11,783,000 |
| % Margin | 14.9% | 11% | 12.8% | 15.4% |
| Other Income/Exp. Net | -$1,028 | -$123,000 | $2,309,000 | -$313,000 |
| Pre-Tax Income | $68,844 | $7,450,000 | $12,172,000 | $11,470,000 |
| Tax Expense | $14,825 | $1,587,000 | $3,667,000 | $2,826,000 |
| Net Income | $54,499 | $5,878,000 | $8,791,000 | $8,693,000 |
| % Margin | 11.7% | 8.6% | 11.4% | 11.4% |
| EPS | 0.17 | 17.33 | 25.74 | 25.32 |
| % Growth | -99% | -32.7% | 1.7% | – |
| EPS Diluted | 0.16 | 17.28 | 25.69 | 25.22 |
| Weighted Avg Shares Out | 329,970 | 340,162 | 342,159 | 344,745 |
| Weighted Avg Shares Out Dil | 340,162 | 340,162 | 341,364 | 344,745 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,737 | $0 | $1,173,000 | $148,000 |
| Interest Expense | $2,805 | $122,000 | $0 | $0 |
| Depreciation & Amortization | $31,711 | $4,497,000 | $4,399,000 | $4,507,000 |
| EBITDA | $103,360 | $12,070,000 | $18,485,000 | $15,830,000 |
| % Margin | 22.1% | 17.6% | 23.9% | 20.7% |